ArticleBMC musculoskeletal disorders2026
Psoas muscle mass measurement in assessment of imminent fracture risk after vertebral fracture: a single-center case-control study.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sarcopenia Versus Systemic Inflammation as Predictors of New Vertebral Fractures After Vertebroplasty or Kyphoplasty: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesTo assess the predictive value of CT value and cross-sectional area (CSA) of the psoas muscle at the L3 level for imminent fracture risk after vertebral fracture and compare with quantitative CT based finite element analysis (QCT-FEA) and volumetric bone mineral density (vBMD) measurement. MATERIALS &
methodsForty patients with imminent fractures following prior thoracolumbar fragility fractures and fifty-one matched controls without re-fracture during at least a two-year follow-up were retrospectively identified from administrative databases. The CT value and the CSA of the psoas muscle at L3 levels were measured with baseline CT images. Additionally, QCT-FEA was performed to estimate the vertebral bone strength of L1 and measured the vBMD. The predictive values of these factors were assessed using logistic regression analysis and ROC curves.
resultsPatients with imminent fractures had significantly lower psoas muscle CSA (669.5 ± 188.1 vs. 904.2 ± 189.7 mm², P < 0.001), vBMD (65.6 ± 19.6 vs. 78.5 ± 16.0 mg/cm³, P = 0.001), and FE-vertebral strength (564.5 ± 329.9 vs. 783.9 ± 225.6 N, P < 0.001) than controls, while no difference was observed in psoas muscle mean CT value (P = 0.210). Psoas CSA emerged as the strongest independent predictor of imminent fracture (adjusted OR = 5.0, 95%CI: 2.5–11.3, P < 0.001), outperforming vBMD (adjusted OR = 2.2, 95%CI: 1.4–3.8) and FE-vertebral strength (adjusted OR = 2.7, 95%CI: 1.6–4.9). ROC analysis confirmed psoas CSA had the highest AUC among single parameters (0.812, 95%CI: 0.724–0.901), and the combination of psoas CSA and FE-vertebral strength achieved the optimal predictive performance (AUC = 0.866). Stratified analysis in females validated these findings, with psoas CSA showing an even stronger association (adjusted OR = 8.6, 95%CI: 3.4–29.4) and higher AUC (0.850).
conclusionL3 psoas muscle CSA is an independent and superior predictor of imminent fracture risk in patients with prior vertebral fractures compared to QCT-FEA-derived vertebral strength and vBMD. Combining psoas CSA with FE-vertebral strength further enhances predictive efficiency.
trial registrationRetrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.